Mashhadi Mohammad Ali, Koushyar Mohhamad Mahdi, Mohammadi Mehdi
Dept. of Hematology and Oncology, Genetic Research Center , Ali Ebne Abitaleb Hospital, Zahedan University of Medical Sciences, Zahedan, Iran.
Dept. of Hematology and Oncology, Emam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.
Iran J Cancer Prev. 2012 Summer;5(3):130-7.
Acute lymphoblastic leukemia is a lymphoid malignancy, resulting from autonomous proliferation of monoclonal abnormal stem cell. The aim of this study was to evaluate the response rate and prognostic factor of adult patients suffering from acute lymphoblastic leukemia, who were treated with chemotherapy in south east of Iran and demographic methods were used for this study.
This study was conducted in Ali Ebne Abitaleb Hospital in south east of Iran (Zahedan) from 2003-2010. All adult patients with acute lymphoblastic leukemia in hematology ward received Vincristin, Daunorubicin, Cyclophosphamide, Prednisolone and high dose Methotrexate for induction therapy. All patients' information was recorded and multivariate analysis and survival studies were performed by using Kaplan-Meier statistics.
Sixty six adult patients entered. Mean age of them was 33 years old (16-68), that 53 (80.3%) cases were male and 13 cases were female. Fifty one (77.3%) cases experienced complete remission and 15 (22.7%) cases had no remission state. In the following year 53% ( 33) was alive with complete remission and 47% ( 31) were dead. Median survival was 13 months. In the end of study 30 cases were in complete remission and alive and 36 (54.5%) were dead.
Our results were comparable with other studies and minimally better than those studies.
急性淋巴细胞白血病是一种淋巴恶性肿瘤,由单克隆异常干细胞自主增殖引起。本研究旨在评估在伊朗东南部接受化疗的成年急性淋巴细胞白血病患者的缓解率和预后因素,并采用人口统计学方法进行此项研究。
本研究于2003年至2010年在伊朗东南部(扎黑丹)的阿里·伊本·阿比塔莱布医院进行。血液科病房所有成年急性淋巴细胞白血病患者接受长春新碱、柔红霉素、环磷酰胺、泼尼松龙和大剂量甲氨蝶呤进行诱导治疗。记录所有患者的信息,并使用Kaplan-Meier统计方法进行多变量分析和生存研究。
66名成年患者入组。他们的平均年龄为33岁(16 - 68岁),其中53例(80.3%)为男性,13例为女性。51例(77.3%)患者达到完全缓解,15例(22.7%)患者未缓解。在接下来的一年中,53%(33例)处于完全缓解状态存活,47%(31例)死亡。中位生存期为13个月。研究结束时,30例患者处于完全缓解且存活,36例(54.5%)死亡。
我们的结果与其他研究相当,且略优于那些研究。